Cardiodilatin fragment, process for preparing same and use thereof
AssigneeHaemopep Pharma GmbH
InventorsWolf-Georg Forssmann, Jeanette M. Alt, Gerhard Becker, Franz Herbst
Life of this patent
Estimating the term…
Abstract
Described is a peptide fragment which comprises the amino acid sequence 95-126 of ANF/CDD 1-126 (gamma-hANaP) and is formed in the kidney. The fragment urodilatin (ANF/CDD 95-126) has the following amino acid sequence: ##STR1## wherein R.sup.1 and R.sup.2 each represent further peptide fragments of ANF/CDD 1-126 (gamma-hANaP). In the amino acid sequence R.sup.1 is Thr-Ala-Pro-Arg-Ser-Leu-Arg-Arg-Ser-Ser and R.sup.2 is Asn-Ser-Phe-Arg-Tyr. Further described are processes for the preparation and/or recovery of the new peptide fragment and a medicament containing urodilatin (ANF/CDD 95-126) as well as medical indications of the medicament.
Claims10
A process for preparing a peptide having the amino acid sequence 95-126 of ANF/CDD 1-126 (gamma-hANaP), which is designated urodilatin (ANF/CDD 95-126), of the formula ##STR8## comprising step-wise synthesis on a solid phase using amino acids protected by protective groups.
A process for obtaining from ANF/CDD 99-126 a peptide having the amino acid sequence 95-126 of ANF/CDD 1-126 (gamma-hANaP), which is designated urodilatin (ANF/CDD 95-126), of the formula ##STR9## comprising reacting ANF/CDD 99-126 with tetrapeptide Thr-Ala-Pro-Arg, having optional amino-protective groups, removing the optional amino-protective groups, and purifying the resulting product.
A process for obtaining from urine a peptide having the amino acid sequence 95-126 of ANF/CDD 1-126 (gamma-hANaP), which is designated urodilatin (ANF/CDD 95-126), of the formula ##STR10## comprising adding alginic acid to the urine, eluting peptides adsorbed on the alginic acid, fractionating the eluate, and determining the urodilatin (ANF/CDD 95-126)-active fraction.
Dependencies are inferred from the claim text.